---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-26-000018"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2026-07-31T11:06:21+00:00"
generated_at: "2026-07-31T11:10:09.841423+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Werewolf Q2 net income $3.7M on $21M asset sale; cash runway into Q2 2027

## Summary
- Net income of $3.7M vs net loss of $18.0M in Q2 2025; collaboration revenue of $21.0M from JZP898 sale to Jazz.
- Cash and equivalents $22.0M as of June 30, 2026, down from $46.5M at March 31, 2026; expects to fund operations into Q2 2027.
- R&D expenses decreased to $6.2M from $13.1M; G&A increased to $7.7M from $4.4M.
- Exploring strategic alternatives with Piper Sandler; expects data updates on WTX-124 and WTX-330 in H2 2026.

## SEC filing metadata
- accession: 0001785530-26-000018
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2026-07-31T11:06:21+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/0001785530-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/howl-20260731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-26-000018
- JSON: https://secwatch.observer/filing/0001785530-26-000018.json
- Plain text: https://secwatch.observer/filing/0001785530-26-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.